Marco Taglietti, M.D.
President and Chief Executive Officer
Dr. Taglietti has served as Chief Executive Officer of SCYNEXIS since April 2015 and became President of the Company in September 2015. He has been a member of the board since November 2014. He served as Executive Vice President, Research and Development and Chief Medical Officer of Forest Laboratories, Inc. and as President of the Forest Research Institute until its acquisition by Actavis in 2014. Prior to joining Forest Laboratories in 2007, Dr. Taglietti held the position of Senior Vice President, Head of Global Research and Development, at Stiefel Laboratories, Inc., a GSK company, for three years. He joined Stiefel Laboratories after 12 years at Schering-Plough Corporation, where he last held the position of Vice President, Worldwide Clinical Research for Anti-Infectives, Oncology, CNS, Endocrinology and Dermatology. Dr. Taglietti began his pharmaceutical career at Marion Merrell Dow Research Institute. Over the course of his career, he has brought to market 35 different products in the U.S. and internationally. Dr. Taglietti currently serves on the Board of Directors of BioNJ, Inc. and Aquestive Therapeutics, Inc. (Nasdaq: AQST). He received his medical degree and board certifications from the University of Pavia in Italy.
David Angulo, M.D.
Chief Medical Officer
Dr. Angulo joined SCYNEXIS as Chief Medical Officer in June 2015. He previously served as Vice President, Research and Development of Brickell Biotech, Inc. Prior to joining Brickell, Dr. Angulo held various senior positions at Stiefel Laboratories, Inc., a GSK company, including head of the clinical and medical departments. Dr. Angulo was also responsible for several development programs in the anti-infectives area at Schering-Plough Research Institute and was an infectious disease physician in a pediatric hospital. He received his medical degree from the Universidad de Guadalajara, Mexico, and has post-graduate degrees in pediatrics and infectious diseases.
Mr. Sukenick joined SCYNEXIS as General Counsel in November 2017 after over a decade of addressing a diversity of legal challenges faced by innovative life sciences companies at all stages of development. Mr. Sukenick most recently worked at Cooley LLP, where he focused on life sciences litigation and strategic intellectual property management. Prior to that, he worked at Patterson Belknap Webb & Tyler LLP, where he primarily represented pharmaceutical and medical device companies in patent litigation. He started his career at Simpson Thacher & Bartlett LLP, where his practice focused on complex commercial litigation and intellectual property transactional matters. Mr. Sukenick is a registered patent attorney. He obtained a B.S. in Biology and a B.A. in Chemistry from Duke University and a J.D. from Harvard University.
Ivor Macleod, MBA, CPA
Chief Financial Officer
Ivor Macleod is a senior pharmaceutical executive with more than 30 years of financial and operational experience in the life sciences industry. Mr. Macleod joins SCYNEXIS from Athersys, Inc. where he had served as Chief Financial Officer since January of 2020. Mr. Macleod has held multiple financial leadership roles throughout his career both in the United States and Europe. Previously he served as the Chief Financial Officer and Chief Compliance Officer of Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a Japanese research-based human health care company that discovers, develops and markets products globally, from 2015 to 2018. Prior to joining Eisai, Mr. Macleod served as Vice President Finance - Merck Research Labs at Merck & Co., Inc., a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, from 2012 to 2015. Before joining Merck, Mr. Macleod served from 1998 to 2012 at F. Hoffmann-La Roche, Inc., a multinational health care company, in various roles, including as North American Chief Financial Officer from 2000 to 2011 as well as General Manager from 2010 to 2011. Mr. Macleod received his B.Sc. from St. Andrews University in Scotland and his M.B.A. from the University of Arizona. Mr. Macleod is a Certified Public Accountant licensed in Virginia.
Nkechi Azie, M.D., FIDSA
Vice President, Clinical Development and Medical Affairs
Dr. Azie joined SCYNEXIS as Vice President of Clinical Development and Medical Affairs in June 2019. She has more than 25 years of drug development and medical affairs experience in several therapeutic areas. Dr. Azie was most recently Senior Vice President of Medical Affairs at The Medicines Company, where she managed the infectious disease franchise. Previously, she worked at Astellas Pharma as a Senior Director of Medical Affairs, where she was responsible for the antifungal franchise. Prior to that, she was Director of Anti-infective Clinical Development for Pfizer, Inc. Dr. Azie is board certified in internal medicine, clinical pharmacology, and infectious disease and was elected for Infectious Diseases Society of America (IDSA) Fellowship. She holds an executive M.B.A. from the University of Notre Dame Mendoza College of Business, a Bachelor of Medicine, a Bachelor of Surgery and a B.S. from the University of Nigeria College of Medicine and conducted a medical residency and subspecialty training at Indiana University Medical Center.
Glen D. Park, PharmD, MSJ
Vice President, Regulatory Affairs & Quality Assurance
Dr. Park joined SCYNEXIS in 2017 as Executive Director, Regulatory Affairs. He has more than 30 years of experience in the pharmaceutical/biotech/medical device industry in clinical development and regulatory affairs. Dr. Park has led global clinical development of medical products across multiple therapeutic areas, including diabetes, hypertension, Gaucher disease, Fabry disease, renal disease, head lice, and chemotherapy-induced alopecia. He has had primary authorship responsibility for the clinical section of multiple NDAs and managed numerous investigational and marketing applications and regulatory communications with CDER, CBER, and CDRH. Dr. Park received his Doctor of Pharmacy degree from the University of Missouri-Kansas City and a Master of Science in Jurisprudence degree from Seaton Hall Law School.